CIBC Asset Management Inc Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

CIBC Asset Management Inc grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 442.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,832 shares of the biopharmaceutical company’s stock after buying an additional 24,334 shares during the quarter. CIBC Asset Management Inc’s holdings in Alnylam Pharmaceuticals were worth $11,863,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ALNY. First Horizon Corp increased its holdings in shares of Alnylam Pharmaceuticals by 20.7% during the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 28 shares during the period. Yousif Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after acquiring an additional 29 shares during the period. Bessemer Group Inc. grew its holdings in Alnylam Pharmaceuticals by 15.6% during the third quarter. Bessemer Group Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 30 shares during the period. Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares during the period. Finally, Everpar Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 6.3% during the fourth quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 37 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ ALNY opened at $303.05 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $283.10 and a one year high of $495.55. The firm has a market capitalization of $40.46 billion, a PE ratio of 82.80 and a beta of 0.29. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The business has a 50-day moving average price of $307.66 and a two-hundred day moving average price of $349.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company posted ($0.44) EPS. The business’s quarterly revenue was up 96.4% compared to the same quarter last year. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 7,740 shares of company stock valued at $2,420,214 over the last 90 days. Corporate insiders own 0.86% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ALNY. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Needham & Company LLC lowered their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday. Chardan Capital reaffirmed a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Finally, Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.